A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

This is an interventional basic science trial for Dyslipidemias Read More

Inclusion Criteria:

• Be healthy, as determined by medical history and physical examination
• Male participants must be between 18 and 70 years of age and must agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product
• Female participants must be between 40 and 70 years old, and either postmenopausal or with a hysterectomy, and not pregnant and not lactating
• Be on a stable diet and exercise regimen for greater than (>) 3 months prior
• Have a body mass index (BMI) of 25.0 to 35.0 (Part A) or 27.0 to 40.0 (Part B) kilograms per meter squared
• Have fasting triglycerides (TG) between 150 and 499 milligrams per deciliter (mg/dL) (Part B only)
• Have a fasting low-density lipoprotein cholesterol (LDL-c) between 100 and 200 mg/dL (Part B only)
• Have estimated glomerular filtration rate greater than or equal to (≥) 60 milliliters per minute/1.73 meter squared with no proteinuria
• Be normotensive defined as supine systolic blood pressure (BP) less than or equal to (≤) 150 millimeters of mercury (mm Hg) and diastolic BP ≤ 100 mm Hg, without the use of any antihypertensive

Exclusion Criteria:

• Are taking a statin, any proprotein convertase subtilisin/kexin type 9 (PCSK9) medications, or have started taking other TG lowering agents (for example, niacin, fish oils)
• Are currently enrolled in a clinical trial involving an investigational product or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research, or have participated in a clinical trial involving an investigational product or non-approved use of a drug within the last 30 days or within 5 half-lives
• Have an abnormal electrocardiogram or corrected QT or are on antihypertensive treatment
• Have any current or prior history of significant cardiovascular disease
• Show evidence of hepatitis C virus (HCV), Hepatitis B or other chronic liver disease
• Have an alcohol intake that exceeds 7 units per week with no more than 3 units per day, or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 ounces or 360 mL of beer; 5 ounces or 150 mL of wine; 1.5 ounces or 45 mL of distilled spirits), or are a regular user of known drugs of abuse
• Have a history of untreated endocrine illness such as diabetes mellitus
• Have been on medications or supplements for weight loss within 3 months
• Have a history of active neuropsychiatric disease or on pharmacological therapy for such conditions (Part B, only)
• Show evidence of human immunodeficiency virus (HIV) infection
• Have been on medications that are known to inhibit cytochrome P450, family 3, subfamily A (CYP3A) or P-glycoprotein (P-gp), or regularly consume grapefruit
• Have donated blood of more than 500 mL within the last month
• Smoke >10 cigarettes per day or are unwilling to follow smoking rules